Unum
UNM
$75.90
-1.48%
Unum Group is a leading provider of group and individual income protection insurance, centered on disability coverage for employer plans, complemented by life, accident, long-term care, and voluntary benefits sold primarily through brokers across the U.S., U.K., and Poland. It is the dominant domestic group disability insurer, with its Unum US segment generating the bulk of premiums and Colonial Life providing a growing voluntary-benefits franchise, giving it a scale-driven, distribution-heavy identity rather than a capital-light disruptor profile. The current investor narrative has been jolted by a severe third-quarter 2026 earnings shock — a swing to a large net loss and a roughly 24% year-over-year revenue decline reported on November 4 — that triggered a one-day share collapse and reframed the debate around reserve adequacy, claims severity, and closed-block long-term care exposure. Against that, sell-side commentary has emphasized a headline Q3 beat on revenue and EPS versus estimates, while coverage leans constructive on buybacks, premium growth, and margin stabilization; the tension between the reported loss and the 'beat' framing is precisely what is driving volatility and disagreement around the stock.…
UNM
Unum
$75.90
Related headlines
Investment Opinion: Should I buy UNM Today?
Rating: Hold, with a constructive bias. The core thesis is that UNM's Q3 2026 shock — a $419.7 million net loss and a 24.13% YoY revenue decline — is most likely a non-cash reserve event rather than a cash-drain or solvency problem, given $529.6 million of Q3 free cash flow and $1.625 billion of trailing FCF against the accounting loss, but the evidence is not yet conclusive enough to chase the stock. The analyst consensus of 'buy' (mean rating 1.69, 10 Buy / 3 Hold / 0 Sell) with an average target of $96.23 implies 20.5% upside, and the fact that even the lowest target of $85.0 sits 6.5% above the current $79.84 is a strong signal that the Street views the loss as a one-off.
Supporting evidence is genuinely two-sided. On valuation, the trailing PE of 18.1x compresses to a forward PE of 9.13x on consensus EPS of $12.55, while price-to-book of 1.20x and price-to-sales of 1.02x are modest in absolute terms — though P/B sits near the top of its 0.44x-1.32x multi-year range, so the stock is not cheap on book. Growth has flipped negative: Q3 revenue of $2.548 billion versus a $3.29-$3.36 billion run-rate in Q1/Q2 2026, with gross margin collapsing to 18.56% from 40.27% in Q1 and operating margin at -19.45%. Profitability on a trailing basis is thin (net margin 5.66%, ROE 6.64%, ROA 0.51%), but cash generation is robust and the balance sheet is conservative at 0.351 debt-to-equity, with a 2.29% dividend yield covered by a 41.5% payout ratio and $198.5 million of Q3 buybacks.
Three risks could invalidate the thesis: a second Closed Block LTC reserve strengthening (the $448.0 million segment is the likely source of the charge), continued revenue contraction that forces analysts to cut the $12.55 EPS estimate and mechanically re-rate the 9.13x forward multiple higher, and a break below the $73.95 November 5 low that would confirm the gap-down as a trend change. This Hold would upgrade to Buy if Q4 restores gross margin toward the 39-40% Q1/Q2 level and confirms the charge was one-time, or on a pullback toward the $69.02 52-week low that widens the risk/reward; it would downgrade to Sell on any second reserve charge or if consensus EPS is cut materially below $12. The valuation verdict is fairly valued to modestly undervalued on forward earnings but expensive on book value — the market is pricing recovery, not distress, which leaves limited margin of safety.
Sign up to view all
UNM 12-Month Price Forecast
UNM presents a genuinely balanced setup: the cash-flow evidence ($529.6 million Q3 FCF, $1.625 billion trailing FCF, 0.351 debt-to-equity) argues the Q3 loss is an accounting event, while the margin and revenue data (18.56% gross margin, -24.13% YoY revenue) argue the underlying business has a real problem that has not been explained. The unanimous analyst cohort with no target below $85.0 is a powerful signal, but the 9.13x forward PE already prices in a full earnings recovery, so the stock is not cheap on the numbers that matter if estimates slip. With a beta of just 0.231, the outcome will be driven almost entirely by company-specific news rather than macro, making the Q4 print the single decisive event. I would upgrade to bullish on a clean Q4 with gross margin back above 35% and no second charge, and downgrade to bearish on any second reserve strengthening or a break below $73.95.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Unum's 12-month outlook, with a consensus price target around $96.69 and implied upside of +27.4% versus the current price.
Average Target
$96.69
13 analysts
Implied Upside
+27.4%
vs. current price
Analyst Count
13
covering this stock
Price Range
$85 - $111
Analyst target range
Coverage is solid with 13 analysts and a consensus recommendation of 'buy' (mean rating 1.69), split 10 Buy, 3 Hold, and 0 Sell. The average target price of $96.23 implies roughly 20.5% upside from the current $79.84, and notably even the lowest target of $85.0 sits about 6.5% above the current price — a rare configuration where no analyst sees downside. Consensus EPS of $12.55 and revenue of $13.18 billion underpin that optimism, though the Q3 loss makes those estimates a high bar.
The target range of $85.0 to $108.0 is wide at roughly 27% of the midpoint, signaling meaningful uncertainty about the earnings recovery. The $108 high target likely assumes reserve issues prove contained, buybacks continue at pace, and forward EPS of $12.55 is achieved, driving multiple re-rating toward book value plus growth. The $85 low target prices in a slower normalization and persistent margin pressure. Institutional activity skews constructive — JP Morgan upgraded to Overweight from Neutral on November 9, and Wells Fargo, Barclays, Truist, KBW, and Evercore all reiterated bullish ratings in early November — but Morgan Stanley's Equal Weight stance and the post-shock timing suggest the Street is supportive yet still waiting for proof that the Q3 loss was a one-off.
Bulls vs Bears: UNM Investment Factors
The bear case currently has stronger near-term evidence: a -24.13% YoY revenue decline, a swing to a -$419.7 million net loss, gross margin collapsing from 40.27% to 18.56%, and a stock down 14.45% over three months with -11.62% relative underperformance versus SPY. The bull case rests on the fact that the loss appears non-cash — $529.6 million of Q3 free cash flow against a $419.7 million accounting loss — a conservative 0.351 debt-to-equity ratio, a 9.13x forward PE, and a unanimous analyst cohort with no target below $85.0. The single most important tension is whether the Q3 charge was a one-time reserve strengthening in the Closed Block LTC book or the first sign of a recurring claims-severity problem; a clean Q4 that restores gross margin toward the 39-40% Q2/Q1 level would validate the bulls and likely close the gap to the $96.23 average target, while any second charge would confirm the bears and put the $69.02 52-week low in play.
Bullish
- No analyst sees downside: All 13 covering analysts have targets above the current $79.84 price, with the lowest at $85.0 (6.5% upside) and the average at $96.23 (20.5% upside). The 10 Buy / 3 Hold / 0 Sell split (mean rating 1.69) is a rare configuration that suggests the Street views the Q3 shock as a one-off rather than a thesis-breaker.
- Loss is non-cash, cash flow intact: Despite a $419.7 million Q3 net loss, UNM generated $529.6 million of free cash flow and $561.5 million of operating cash flow in the quarter, with $1.625 billion of trailing FCF. That gap between accounting loss and cash generation points to reserve strengthening or investment marks rather than a cash drain, and it comfortably funds the $198.5 million of buybacks and $80.0 million of dividends paid in Q3.
- Forward PE of 9.1x prices recovery: The trailing PE of 18.1x compresses to a forward PE of 9.13x on consensus EPS of $12.55, implying the market expects earnings to more than double. Price-to-book of 1.20x and a 2.29% dividend yield with a 41.5% payout ratio mean investors are being paid to wait while the earnings base normalizes.
- Balance sheet provides a floor: Debt-to-equity of just 0.351 is conservative for an insurer, and the $69.02 52-week low sits only 13.5% below the current price. With a beta of 0.231, UNM's normal trading character is roughly 77% less volatile than the market, so the 17.8% single-day gap on November 4 is an extraordinary idiosyncratic dislocation rather than a structural de-rating.
Bearish
- Revenue collapsed 24.1% YoY: Q3 2026 revenue fell to $2.548 billion from $3.358 billion a year earlier, a -24.13% YoY decline that breaks a run-rate of roughly $3.29-$3.36 billion in Q1 and Q2 2026. For a scale-driven insurer whose top line should be stable, a decline of this magnitude signals a segment-level problem that has not yet been explained.
- Margins swung violently negative: Gross margin collapsed to 18.56% in Q3 from 39.19% in Q2 and 40.27% in Q1, while operating margin fell to -19.45% from +10.01%. Negative EBITDA of -$461.3 million and EPS of -$2.65 versus +$1.61 in Q2 point to reserve strengthening or investment losses, not ordinary claims volatility.
- Consensus EPS is a very high bar: The $12.55 consensus EPS underpinning the 9.13x forward PE requires earnings to more than double from a base that just produced a -$2.65 quarterly loss. With Q3 already a large miss on the bottom line, the estimates carry meaningful downgrade risk, and the PEG ratio of -0.33 confirms the earnings base is too distorted to anchor valuation.
- Momentum is decisively negative: UNM is down 12.71% over one month and 14.45% over three months, versus a 2.20% six-month decline, meaning the damage is concentrated and accelerating. Relative strength versus SPY is -10.45% over one month and -11.62% over three months, and the stock sits at only 39.1% of its 52-week range, 21.2% below the $96.77 high.
UNM Technical Analysis
UNM is in a damaged but not broken longer-term trend: the stock is up 3.69% over the past year and 3.38% year-to-date, yet it sits at $79.84, only 39.1% of the way through its 52-week range of $69.02 to $96.77 — closer to the floor than the ceiling. That positioning signals a stock that has surrendered most of its 2026 gains and is testing whether the mid-$70s area represents a durable value floor or a falling knife after a violent repricing. The 52-week high of $96.77 remains 21.2% above the current price, underscoring how much ground has been lost from the September peak.
Short-term momentum is decisively negative and sharply divergent from the flattish one-year trend. The stock is down 12.71% over one month and 14.45% over three months, versus a 2.20% six-month decline, meaning the damage is concentrated in the recent window and accelerating rather than fading. The catalyst is visible in the price series: UNM closed at $91.03 on November 3 and gapped to $74.79 on November 4, a roughly 17.8% single-session collapse, before rebounding to $79.84 by November 13. Relative strength confirms the underperformance — negative 10.45% versus SPY over one month and negative 11.62% over three months — and with a short ratio of 3.24, bearish positioning is meaningful but not extreme, leaving room for either squeeze or further pressure.
Key technical levels are now well defined by the post-shock range. Support sits at the November 5 low close of $73.95, with the 52-week low of $69.02 as the deeper backstop — a break below $73.95 would confirm the gap-down as a trend change rather than a one-off shock. Resistance is layered at the $90-$92 shelf where the stock traded for months before the gap, with the $96.77 high as the full-recovery target. Notably, UNM's beta of just 0.231 implies roughly 77% less volatility than the market, so this 17.8% single-day move is an extraordinary idiosyncratic event for a low-beta name, and the maximum drawdown of -23.42% shows how unusual this dislocation is relative to its normal trading character.
Beta
0.23
0.23x market volatility
Max Drawdown
-23.4%
Largest decline past year
52-Week Range
$69-$97
Price range past year
Annual Return
-0.5%
Cumulative gain past year
| Period | UNM Return | S&P 500 |
|---|---|---|
| 1m | -19.0% | -9.7% |
| 3m | -13.5% | -9.9% |
| 6m | -10.2% | -7.5% |
| 1y | -0.5% | +4.7% |
| ytd | -1.7% | +1.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UNM Fundamental Analysis
The revenue trajectory has deteriorated abruptly. Q3 2026 revenue came in at $2.548 billion, down 24.13% year-over-year from $3.358 billion in Q3 2025, a stark reversal from the roughly $3.29-$3.36 billion run-rate in Q1 and Q2 2026. Segment data shows Unum US at $2.077 billion, Colonial Life at $520.8 million, Closed Block at $448.0 million, and Unum International at $331.1 million, meaning the core U.S. franchise still dominates but the consolidated top line was dragged down hard in the latest quarter. The growth trend has flipped from stable to contracting, which undermines the investment case until the source of the Q3 revenue shortfall is clarified.
Profitability swung violently negative. Q3 2026 produced a net loss of $419.7 million and EPS of -$2.65, versus net income of $256.9 million (EPS $1.61) in Q2 2026 and $232.0 million (EPS $1.41) in Q1 2026. Gross margin collapsed to 18.56% in Q3 from 39.19% in Q2 and 40.27% in Q1, while operating margin fell to -19.45% from +10.01% in Q2. The company's trailing net margin of 5.66% and operating margin of 7.15% mask this quarter's damage, and the negative EBITDA of -$461.3 million in Q3 is a red flag for an insurer whose earnings should be relatively stable — pointing to reserve strengthening or investment losses rather than ordinary claims volatility.
Balance sheet and cash generation remain the relative bright spots. Debt-to-equity is modest at 0.351, and trailing free cash flow is $1.625 billion, with Q3 2026 free cash flow of $529.6 million and operating cash flow of $561.5 million despite the accounting loss — evidence that the hit is non-cash in nature. ROE of 6.64% and ROA of 0.51% are weak for an insurer, and the company continued returning capital with $198.5 million of buybacks and $80.0 million of dividends in Q3. The dividend yield of 2.29% with a payout ratio of 41.5% looks sustainable on cash flow, but the gap between reported losses and cash generation is the central question investors must resolve.
Quarterly Revenue
$2.5B
2026-09
Revenue YoY Growth
-24.1%
YoY Comparison
Gross Margin
18.6%
Latest Quarter
Free Cash Flow
$1.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UNM Overvalued?
Because trailing net income remains positive on a TTM basis (net margin 5.66%), the PE ratio is the appropriate primary metric, and it tells a bifurcated story: trailing PE of 18.1x versus forward PE of 9.13x. That roughly 50% compression implies the market expects earnings to more than double, consistent with consensus EPS estimates of $12.55 — a forecast that looks aggressive given the Q3 loss and will require a sharp normalization of claims and reserves. The PEG ratio of -0.33 is not meaningful given the distorted earnings base.
On peer comparison, UNM trades at a price-to-book of 1.20x and price-to-sales of 1.02x, with EV/Sales of 1.16x and EV/EBITDA of 13.5x — multiples that are modest in absolute terms but hard to benchmark precisely because industry-average data is not available in the provided dataset. The forward PE of 9.13x is well below the trailing 18.1x and below where life insurers typically trade when earnings are stable, suggesting the market is applying a discount for uncertainty rather than pricing in growth. The 2.29% dividend yield and 1.20x book value imply the stock is being valued more on balance-sheet safety than on earnings power.
Historically, UNM's PE has ranged from roughly 4.3x (Q3 2024) to 84.5x (Q3 2025), with the current 18.1x sitting in the middle of that band but well above the 9.5x-13.9x levels seen through much of 2024-2025. Price-to-book at 1.20x is near the upper end of its 0.44x-1.32x multi-year range, while price-to-sales at 1.02x is far below the 3.0x-5.5x levels of recent quarters — a divergence that reflects the revenue collapse more than a valuation opportunity. The market is pricing in recovery, not distress, which leaves limited margin of safety if Q4 fails to normalize.
PE
18.1x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 4x~19x
vs. Industry Avg
11.7x
Industry PE ~11.7x*
EV/EBITDA
13.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are elevated and quantifiable. The Q3 2026 net loss of $419.7 million and EPS of -$2.65 came with negative EBITDA of -$461.3 million and a gross margin collapse to 18.56% from 40.27% in Q1, which for an insurer implies reserve strengthening rather than routine claims volatility. Revenue concentration is a structural vulnerability: Unum US generated $2.077 billion of the $2.548 billion Q3 total (81.5%), so a single segment's claims experience can swing consolidated results, and the Closed Block's $448.0 million of long-term care exposure is the most likely source of the charge. The mitigant is that the hit appears non-cash — Q3 free cash flow of $529.6 million and operating cash flow of $561.5 million against a $419.7 million accounting loss — with debt-to-equity of only 0.351 and $1.625 billion of trailing FCF, though ROE of 6.64% and ROA of 0.51% are weak for the sector and leave little cushion if margins do not normalize. Market and competitive risks center on valuation compression and sentiment. The trailing PE of 18.1x sits in the middle of a historical band that has ranged from 4.3x to 84.5x, while price-to-book of 1.20x is near the top of its 0.44x-1.32x multi-year range — meaning the stock is not cheap on book value even after the drawdown. The 9.13x forward PE embeds consensus EPS of $12.55, so any downward revision mechanically raises the multiple and invites further de-rating; the PEG ratio of -0.33 confirms the earnings base cannot anchor valuation. With a beta of just 0.231, UNM is normally insulated from macro swings, so the -10.45% one-month relative underperformance versus SPY is almost entirely idiosyncratic, and the 3.24 short ratio leaves room for further pressure if Q4 disappoints. The worst-case scenario is a second reserve strengthening in the Closed Block LTC book combined with continued revenue contraction, which would force analysts to cut the $12.55 EPS estimate and abandon the unanimous above-market target structure. In that chain, the stock would retest the November 5 low close of $73.95 (-7.4% from $79.84) and then the 52-week low of $69.02 (-13.5%), with the -23.42% maximum drawdown as a guide to how far a full de-rating could extend — roughly $61 if the historical drawdown repeated from the current price. A realistic adverse case is therefore a -13.5% to -23% loss to the $69.02 low or below, versus 20.5% upside to the $96.23 average target, a roughly symmetric risk/reward that only turns favorable if Q4 confirms the charge was one-time.
FAQ
Ranked by severity, the first risk is reserve adequacy in the Closed Block long-term care book, which generated $448.0 million of Q3 revenue and is the most likely source of the $419.7 million net loss and -$461.3 million EBITDA; a second strengthening would validate the recurring-claims thesis and likely drive the stock toward the $69.02 52-week low. Second is earnings-estimate risk: the 9.13x forward PE rests entirely on $12.55 consensus EPS, so any material cut mechanically re-rates the multiple higher and invites downgrades, with the PEG of -0.33 confirming the base is too distorted to anchor valuation. Third is revenue concentration and contraction — Unum US produced $2.077 billion of the $2.548 billion Q3 total (81.5%) while consolidated revenue fell 24.13% YoY, so a single segment's claims experience swings the whole company. Fourth is valuation and sentiment risk: P/B of 1.20x is near its multi-year ceiling, the stock is down 14.45% over three months with -11.62% relative underperformance versus SPY, and a 3.24 short ratio leaves room for further pressure if Q4 disappoints.
The scenario framework is 50% base, 30% bull, and 20% bear. The base case targets $85.0-$96.23, assuming the Q3 charge proves non-recurring, margins normalize partially rather than fully, and consensus EPS is trimmed modestly from $12.55 while the stock grinds toward the $96.23 average target. The bull case targets $96.23-$108.0 on a clean Q4 with gross margin back above 35%, no second reserve charge, continued buybacks at the Q3 pace of $198.5 million, and follow-through from JP Morgan's November 9 upgrade to Overweight. The bear case targets $69.02-$85.0 on a second Closed Block LTC reserve charge, continued revenue contraction, and an EPS cut below $12, with the -23.42% maximum drawdown as a guide to roughly $61 in a full de-rating. The base case is most likely, and its key assumption is that the Q3 loss was a one-time accounting event rather than the first sign of recurring claims severity.
The answer depends on which multiple you trust, and that bifurcation is the heart of the debate. On forward earnings UNM looks cheap: 9.13x forward PE versus an 18.1x trailing PE implies the market expects earnings to more than double to the $12.55 consensus, and price-to-sales of 1.02x and EV/Sales of 1.16x are modest in absolute terms. On book value it is not cheap — 1.20x P/B sits near the top of its 0.44x-1.32x multi-year range even after the drawdown, and the 18.1x trailing PE is well above the 9.5x-13.9x levels seen through much of 2024-2025. The PEG ratio of -0.33 is meaningless given the distorted earnings base, and EV/EBITDA of 13.5x is not a discount multiple. Net, the stock is fairly valued to modestly undervalued on forward earnings but expensive on book, meaning the market is already pricing a recovery rather than distress — leaving limited margin of safety if the $12.55 EPS estimate slips.
From a pure risk/reward standpoint UNM is a reasonable but not compelling buy at $79.84: the analyst average target of $96.23 implies 20.5% upside and even the lowest of the 13 targets, $85.0, sits 6.5% above the current price, a configuration where no covering analyst sees downside. The valuation supports that — a 9.13x forward PE on consensus EPS of $12.55, 1.20x book, and a 2.29% dividend yield — while the balance sheet is conservative at 0.351 debt-to-equity and Q3 free cash flow of $529.6 million shows the $419.7 million loss was non-cash. The offsetting risk is real: a -24.13% YoY revenue decline, gross margin at 18.56% versus 40.27% in Q1, and a -13.5% to -23% path to the $69.02 52-week low if a second reserve charge lands. It is a good buy primarily for patient value investors who can tolerate a binary Q4 event and want a low-beta (0.231) name with a 2.29% yield while waiting for proof the charge was one-time; it is a poor buy for anyone needing near-term momentum or earnings visibility.
UNM is structurally a long-term holding but tactically a short-term event trade right now, and the two should be separated. Structurally, it is a mature, scale-driven insurer with 10,910 employees, a 2.29% dividend yield covered by a 41.5% payout ratio, a conservative 0.351 debt-to-equity ratio, and a beta of just 0.231 — a profile suited to multi-year value investors seeking low-volatility financial exposure with income, not to momentum traders. Tactically, the 17.8% single-day gap on November 4 and the 8.0% bounce from the $73.95 November 5 low to $79.84 mean the next move is binary on the Q4 print, so anyone initiating should expect a minimum holding period of at least two to three quarters (roughly 6-9 months) to see whether margins normalize and the reserve question is settled. A shorter horizon is only appropriate for traders working the defined $73.95 support and $90-$92 resistance range with tight stops.

